INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on May 21, 2020. The report details a corporate action involving a reverse stock split of the company's common stock, effective May 26, 2020.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes.
Material Changes
- Reverse Stock Split: The Company implemented a 1-for-20 reverse stock split.
- Share Count Reduction: Outstanding shares decreased from 157,774,336 to 7,888,717 (subject to fractional share adjustments).
- Derivative Adjustments: Stock options, warrants, and convertible notes were adjusted proportionally, with exercise and conversion prices increased accordingly.
- Trading Symbol: The ticker symbol remains "INVO" on OTCMKTS, but a "D" suffix was applied for 20 business days to indicate the split.
- CUSIP Change: The new CUSIP number is 44984F 203.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of specific risks beyond the mechanics of the stock split. The primary operational impact is the administrative adjustment of share counts and derivative instruments.
Investor Verification Checklist
- Verify the new share count of 7,888,717 in brokerage accounts post-May 26, 2020.
- Confirm the adjusted exercise prices for any held stock options or warrants.
- Check the updated CUSIP number (44984F 203) for accurate trade settlement.
- Review the press release (Exhibit 99.1) for any additional details on fractional share settlement procedures.